Current Status and Future Outlook of Stem Cell and PRP Therapies in the Self-Pay Healthcare Market, 2026

Current Status and Future Outlook of Stem Cell and PRP Therapies in the Self-Pay Healthcare Market, 2026

～Growth Opportunities in Self-Pay Healthcare: Insights into Changing International Patient Demand, Cell Processing Systems, and Safety / Efficacy Assessment～

自由診療に於ける幹細胞治療・PRP療法の現状と将来性分析 2026 英語版

Sample

※You can view this file without registering for an account.

Key Highlights of the Report
  • Changes in International Patient Demand and Behavior
    Examines international patient trends across key markets, including China, Vietnam, Thailand, and Taiwan, focusing on first-time and repeat patients and conversion rates from inquiries to treatments.
  • Cell Processing Practices and Adoption of Related Products
    Examines in-house and outsourced cell processing practices, including outsourcing partners, costs, post-culture shipping temperatures, and the equipment, reagents, and PRP kits used by medical institutions.
  • Safety and Efficacy Testing / Challenges Faced by Medical Institutions
    Examines cell safety and efficacy testing practices, the reasons for conducting or not conducting these tests, future treatment strategies, and interest in adopting new regenerative medicine and cell therapies.

The market for regenerative medicine and cell therapy under Japan’s Act on the Safety of Regenerative Medicine continued to grow in 2025, fueled by inbound medical tourism. Althoughgrowth is expected to slow due to a decline in patient numbers from China, the market is forecast to expand by 7% in 2026, supported by growing patient numbers from other Asian countries.

Meanwhile, recent medical incidents have highlighted the growing importance of ensuring safety and efficacy. This report analyzes market trends and future prospects for self-pay regenerative medicine and cell therapy, as well as testing practices, needs, and challenges at medical institutions.

商品管理番号 AA10010221
発刊日 2026-10-30
体裁 A4横 / 35ページ
発行 株式会社シード・プランニング
備考 書籍版：簡易製本。マルチクライアントレポート（当社直販のみの販売）
自由診療に於ける幹細胞治療・PRP療法の現状と将来性分析 2026（日本語版）ご購入のお客様には割引特典がございます。お問い合わせください。
レポートの利用範囲とご利用条件はこちら
コーポレート版がご不明の際は
レポートの利用範囲とご利用条件をご覧ください。
内訳
販売価格
（単価 × 入数）
 注文数

書籍版、PDF版

品番
AA10010221_01
追加オプション
  • 単品提供形態A
販売価格
（単価 × 入数）
350,000円(税込385,000円)
（350,000円 × 1）
注文数

書籍版+PDF版セット

品番
AA10010221_02
追加オプション
  • セット提供形態A
販売価格
（単価 × 入数）
380,000円(税込418,000円)
（380,000円 × 1）
注文数

PDFコーポレート版

品番
AA10010221_03
追加オプション
  • 単品提供形態B
販売価格
（単価 × 入数）
700,000円(税込770,000円)
（700,000円 × 1）
注文数

書籍版+PDFコーポレート版セット

品番
AA10010221_04
追加オプション
  • セット提供形態B
販売価格
（単価 × 入数）
760,000円(税込836,000円)
（760,000円 × 1）
注文数
※税込価格は目安です。最終的な消費税額は税抜合計額から計算されるため、変動する場合があります。

Study Overview

Study population
Medical institutions providing Class II and/or Class III regenerative medicine

Participating institutions (45)
Institutions providing both Class II and Class III regenerative medicine: 19 institutions
Institutions providing Class II regenerative medicine: 26 institutions

Survey Method
Online and In-Person Interviews

Fieldwork period
August-September 2026
Note: Dental PRP therapy and cancer immunotherapy are excluded from the analysis of Class III regenerative medicine.

Who Should Use This Report?

This report is intended for:
　○Contract cell processing providers
　○Manufacturers of cell culture equipment, reagents, and consumables
　○Cell testing and evaluation service providers
　○Medical institutions providing regenerative medicine and cell therapies
It provides valuable insights for identifying market opportunities, guiding product and service
development, and developing business strategies.

Contents

Tabulation and Analysis
　1. Executive Summary
　2. Conditions treated with stem cell, PRP and fibroblast therapies
　3. Annual patient numbers
　4. International patient trends
　5. Treatment fees by type of regenerative medicine and cell therapy
　6. Proportion of patients interested in regenerative medicine and cell therapy who receive treatment
　7. Locations where therapeutic cells are processed
　8. Number of culture staff at institutions performing cell culture in-house
　9. Cell processing locations and products used for in-house cell processing
　10. Cell processing contractors, outsourcing costs and material selection
　11. Number of patients receiving cultured stem cell therapy by cell culture provider
　12. Post-culture shipping temperatures for institutions outsourcing stem cell culture
　13. Challenges and issues in regenerative medicine and cell therapy
　14. Cell safety testing practices
　15. Cell efficacy testing practices
　16. Potential applications to other diseases and treatments
　17. Future treatment strategies
　18. Market size trends for stem cell, PRP and fibroblast therapies

Survey Questionnaire

おすすめ商品